Loading clinical trials...
Loading clinical trials...
EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction
Conditions
Interventions
Empagliflozin
Placebo
Locations
439
United States
Advanced Cardiovascular LLC
Alexander City, Alabama, United States
Grandview Medical Center
Birmingham, Alabama, United States
Heart Center Research, LLC
Huntsville, Alabama, United States
Mercy Gilbert Medical Center
Gilbert, Arizona, United States
Arkansas Cardiology, PA
Little Rock, Arkansas, United States
Comprehensive Cardiovascular Medical Group
Bakersfield, California, United States
Start Date
December 16, 2020
Primary Completion Date
November 5, 2023
Completion Date
November 5, 2023
Last Updated
January 7, 2025
NCT07478003
NCT07142265
NCT06939738
NCT05168462
NCT04528511
NCT04162171
Lead Sponsor
Boehringer Ingelheim
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions